Phase II trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for progressive disease after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell (mcc) renal cell carcinoma (RCC): Results by independent imaging review and subgroup analyses

This article has no abstract
Epistemonikos ID: ee15168cbdf2b061d8f001dafef4e5b423d73528
First added on: Feb 12, 2025